These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16886268)

  • 1. Defining the cost of cure: infertility among female survivors of lymphoma.
    Stern CJ; Seymour JF
    Leuk Lymphoma; 2006 Apr; 47(4):574-5. PubMed ID: 16886268
    [No Abstract]   [Full Text] [Related]  

  • 2. Fertility status among women treated for aggressive non-Hodgkin's lymphoma.
    Elis A; Tevet A; Yerushalmi R; Blickstein D; Bairy O; Dann EJ; Blumenfeld Z; Abraham A; Manor Y; Shpilberg O; Lishner M
    Leuk Lymphoma; 2006 Apr; 47(4):623-7. PubMed ID: 16690520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoidosis following escalated BEACOPP chemotherapy for stage IV Hodgkin lymphoma.
    Cho KK; Lyes SM; Shetty A
    Intern Med J; 2019 Apr; 49(4):547-548. PubMed ID: 30957369
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.
    Behringer K; Thielen I; Mueller H; Goergen H; Eibl AD; Rosenbrock J; Halbsguth T; Eichenauer DA; Fuchs M; Reiners KS; Renno JH; van der Ven K; Kuehr M; von Wolff M; Diehl V; Engert A; Borchmann P
    Ann Oncol; 2012 Jul; 23(7):1818-25. PubMed ID: 22228451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):9-10. PubMed ID: 27007004
    [No Abstract]   [Full Text] [Related]  

  • 7. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
    Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
    Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol.
    Gupta VG; Gogia A; Sharma V; Mallick S
    Turk J Haematol; 2018 Aug; 35(3):213-214. PubMed ID: 29856361
    [No Abstract]   [Full Text] [Related]  

  • 11. Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma.
    Arranz R; Pérez G; Steegmann JL; Cámara R; Tomás JF; Figuera A; Vazquez L; Fernández-Rañada JM
    Am J Hematol; 1991 Sep; 38(1):75-6. PubMed ID: 1716853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigations in aggressive non-Hodgkin lymphoma.
    Jonathan F
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
    [No Abstract]   [Full Text] [Related]  

  • 14. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
    Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
    Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
    Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
    [No Abstract]   [Full Text] [Related]  

  • 18. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V; Fuchs M;
    Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.